Cite
Fukazawa-Shinotsuka M, Saito T, Abe M, et al. Maxacalcitol Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Secondary Hyperparathyroidism in Patients Receiving Maintenance Hemodialysis. Drug Res (Stuttg). 2021;72(1):23-33doi: 10.1055/a-1581-7609.
Fukazawa-Shinotsuka, M., Saito, T., Abe, M., Iida, S., Wang, I. T., Terao, K., Chen, H. H., & Liu, M. C. (2022). Maxacalcitol Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Secondary Hyperparathyroidism in Patients Receiving Maintenance Hemodialysis. Drug research, 72(1), 23-33. https://doi.org/10.1055/a-1581-7609
Fukazawa-Shinotsuka, Mizuki, et al. "Maxacalcitol Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Secondary Hyperparathyroidism in Patients Receiving Maintenance Hemodialysis." Drug research vol. 72,1 (2022): 23-33. doi: https://doi.org/10.1055/a-1581-7609
Fukazawa-Shinotsuka M, Saito T, Abe M, Iida S, Wang IT, Terao K, Chen HH, Liu MC. Maxacalcitol Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Secondary Hyperparathyroidism in Patients Receiving Maintenance Hemodialysis. Drug Res (Stuttg). 2022 Jan;72(1):23-33. doi: 10.1055/a-1581-7609. Epub 2021 Sep 06. PMID: 34488237.
Copy
Download .nbib